Article(id=1330228549761478940, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330228429355593866, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2022.09.020, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1647187200000, receivedDateStr=2022-03-14, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1795080800714, onlineDateStr=2026-11-19, pubDate=1662739200000, pubDateStr=2022-09-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795080800714, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795080800714, creator=13701087609, updateTime=1795080800714, updator=13701087609, issue=Issue{id=1330228429355593866, tenantId=1146029695717560320, journalId=1319690329412173987, year='2022', volume='43', issue='9', pageStart='1071', pageEnd='1221', issueExtLink='null', onlineDate='null', pubDate='1662739200000', pubDateStr='2022-09-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795080772007, creator='13701087609', updateTime=1795084787841, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330245273550435048, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330228429355593866, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330245273550435049, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330228429355593866, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1199, endPage=1206, ext={EN=ArticleExt(id=1330228549946028317, articleId=1330228549761478940, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Progress on cardiovascular outcomes of glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes mellitus, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) is a new class of hypoglycemic drugs, which is increasingly important in the treatment of type 2 diabetes mellitus (T2DM) due to its outstanding effects of hypoglycemia, weight loss and low risk of hypoglycemia. Over the past several years, the developer has completed seven cardiovascular outcome trial (CVOT) involving liraglutide, once-weekly long-acting exenatide, lixisenatide, abirlutide, duraglutide, semaglutide as a subcutaneous injection, and semaglutide as an oral formulation. The cardiovascular outcomes of all GLP-1 RAs were found to be noninferior to placebo, and some GLP-1 RAs were found to be superior. The results of these trials have changed national guidelines for medical treatment of T2DM. This article reviewed 7 CVOTs of GLP-1 RAs, in order to provide more support for clinical medication.

, authors=Shuyun SHEN, authorsList=Shuyun SHEN, authorCompany=null, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330228550193492256, articleId=1330228549761478940, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=胰高血糖素样肽-1受体激动剂对2型糖尿病患者的心血管结局, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1 RA)是一类新型降糖药物,由于降糖、减重效果突出且引发低血糖的风险较低,因此在2型糖尿病(type 2 diabetes mellitus,T2DM)的治疗中越来越重要。在过去的几年中,开发公司针对利拉鲁肽、艾塞那肽一周1次长效制剂、利司那肽、阿必鲁肽、度拉鲁肽、司美格鲁肽皮下注射剂和司美格鲁肽口服制剂,完成了7项心血管结局试验(cardiovascular outcome trial,CVOT),并发现所有GLP-1 RAs的心血管结果都非劣效于安慰剂,部分GLP-1 RAs具有优效性。这些试验结果改变了各国关于T2DM的药物治疗指南。该文综述了GLP-1 RAs的7项CVOTs,以期为临床用药提供更多的支持。

, authors=沈舒云, authorsList=沈舒云, authorCompany=null, correspAuthors=null, authorNote=

沈舒云,工程师,研究方向:仿制药选题。

, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=lrNiTYYI2zYNEyEol09nfQ==, magXml=U9J/jZHCcswYzdS3ZfinvQ==, pdfUrl=null, pdf=lvUEJRkTZZPJGNYhIa6bXQ==, pdfFileSize=1363372, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=h5bWHeXAQ6x6RSk+BtEBqw==, mapNumber=null, fund=null)}, authors=[Author(id=1330228550550008101, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330228550621311271, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, authorId=1330228550550008101, language=EN, stringName=Shuyun SHEN, firstName=Shuyun, middleName=null, lastName=SHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Qilu Pharmaceutical Co., Ltd., Jinan 250101, Shandong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228550696808744, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, authorId=1330228550550008101, language=CN, stringName=沈舒云, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=齐鲁制药有限公司,山东 济南 250101, bio={"content":"

沈舒云,工程师,研究方向:仿制药选题。

"}, bioImg=null, bioContent=

沈舒云,工程师,研究方向:仿制药选题。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228550461927713, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, xref=null, ext=[AuthorCompanyExt(id=1330228550474510626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, companyId=1330228550461927713, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Qilu Pharmaceutical Co., Ltd., Jinan 250101, Shandong Province, China), AuthorCompanyExt(id=1330228550482899235, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, companyId=1330228550461927713, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=齐鲁制药有限公司,山东 济南 250101)])])], keywords=[Keyword(id=1330228550810054953, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, language=EN, orderNo=1, keyword=glucagon-like peptide-1 receptor agonist), Keyword(id=1330228550885552426, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, language=EN, orderNo=2, keyword=type 2 diabetes mellitus), Keyword(id=1330228550948466987, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, language=EN, orderNo=3, keyword=cardiovascular disease), Keyword(id=1330228551061713196, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, language=EN, orderNo=4, keyword=cardiovascular outcome trial), Keyword(id=1330228551133016365, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, language=CN, orderNo=1, keyword=胰高血糖素样肽-1受体激动剂), Keyword(id=1330228551195930926, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, language=CN, orderNo=2, keyword=2型糖尿病), Keyword(id=1330228551284011311, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, language=CN, orderNo=3, keyword=脑血管疾病), Keyword(id=1330228551346925872, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, language=CN, orderNo=4, keyword=心血管结局试验)], refs=[Reference(id=1330228551430811953, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志, 2021, 37(4): 311-398., articleTitle=null, refAbstract=null), Reference(id=1330228551489532210, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Matheus AS, Tannus LR, Cobas RA, et al. Impact of diabetes on cardiovascular disease: an update[J]. Int J Hypertens, 2013, 2013: 653789., articleTitle=null, refAbstract=null), Reference(id=1330228551594389811, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. BYETTA®(exenatide) prescribing information[DB/OL]. (2021-11-04) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021773s044lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1330228551665692980, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. BYDUREON®(exenatide extended-release) prescribing information[DB/OL]. (2021-07-22) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022200s031lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1330228551728607541, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. VICTOZA®(liraglutide) prescribing information[DB/OL]. (2020-11-20) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022341s036lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1330228551791522102, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. ADLYXIN (lixisenatide) prescribing information[DB/OL]. (2021-07-30) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208471s004lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1330228551862825271, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. TRULICITY (dulaglutide) prescribing information[DB/OL]. (2021-09-30) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125469s044lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1330228551934128440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. OZEMPIC (semaglutide) prescribing information[DB/OL]. (2021-04-12) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209637s008lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1330228552001237305, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. RYBELSUS (semaglutide) prescribing information[DB/OL]. (2021-04-30) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213051s006lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1330228552068346170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. XULTOPHY® 100/3.6 (insulin degludec and liraglutide) prescribing information[DB/OL]. (2019-11-15) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208583s014s015lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1330228552143843643, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. SOLIQUA® 100/33 (insulin glargine and lixisenatide) prescribing information[DB/OL]. (2021-07-28) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208673s011lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1330228552202563900, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. TANZEUM (albiglutide) prescribing information[DB/OL]. (2017-12-20) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125431s020lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1330228552257089853, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. Tanzeum®(albiglutide)–Drug discontinuation On July 26, 2017[DB/OL]. [2021-12-01]. https://professionals.optumrx.com/content/dam/optum3/professional-optumrx/news/rxnews/drug-recalls-shortages/drugwithdrawal_tanzeum_2017-0801.pdf., articleTitle=null, refAbstract=null), Reference(id=1330228552328393022, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. Guidance document: diabetes mellitus–evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, 2008[EB/OL]. [2021-12-01]. https://www.fda.gov/regulatory-information/search-fdaguidance-documents/diabetes-mellitus-evaluating-cardiovascularrisk-new-antidiabetic-therapies-treat-type-2-diabetes., articleTitle=null, refAbstract=null), Reference(id=1330228552387113279, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2016, 375(4): 311-322., articleTitle=null, refAbstract=null), Reference(id=1330228552445833536, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Mentz RJ, Bethel MA, Gustavson S, et al. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)[J]. Am Heart J, 2017, 187: 1-9., articleTitle=null, refAbstract=null), Reference(id=1330228552512942401, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2017, 377(13): 1228-1239., articleTitle=null, refAbstract=null), Reference(id=1330228552571662658, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Bentley-Lewis R, Aguilar D, Riddle MC, et al. Rationale, design, and baseline characteristics in evaluation of lixisenatide in acute coronary syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo[J]. Am Heart J, 2015, 169(5): 631-638., articleTitle=null, refAbstract=null), Reference(id=1330228552689103172, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome[J]. N Engl J Med, 2015, 373(23): 2247-2257., articleTitle=null, refAbstract=null), Reference(id=1330228552772989253, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial[J]. Lancet, 2019, 394(10193): 121-130., articleTitle=null, refAbstract=null), Reference(id=1330228552844292422, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial[J]. Lancet, 2018, 392(10157): 1519-1529., articleTitle=null, refAbstract=null), Reference(id=1330228552923984199, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2016, 375(19): 1834-1844., articleTitle=null, refAbstract=null), Reference(id=1330228552986898760, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2019, 381(9): 841-851., articleTitle=null, refAbstract=null), Reference(id=1330228553049813321, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021[J]. Diabetes Care, 2021, 44(Suppl 1): S125-S150., articleTitle=null, refAbstract=null), Reference(id=1330228553116922186, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD[J]. Eur Heart J, 2020, 41(2): 255-323., articleTitle=null, refAbstract=null), Reference(id=1330228553196613963, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=国家卫生健康委员会能力建设和继续教育中心, 孙艺红, 陈康, 等. 糖尿病患者合并心血管疾病诊治专家共识[J]. 中华内科杂志, 2021, 60(5): 421-437., articleTitle=null, refAbstract=null), Reference(id=1330228553255334220, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Longato E, Di Camillo B, Sparacino G, et al. Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes[J]. Eur J Prev Cardiol, 2021, 28(1): 22-29., articleTitle=null, refAbstract=null), Reference(id=1330228553318248781, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Caruso I, Cignarelli A, Giorgino F. Heterogeneity and similarities in GLP-1 receptor agonist cardiovascular outcomes trials[J]. Trends Endocrinol Metab, 2019, 30(9): 578-589., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1330228550461927713, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, xref=null, ext=[AuthorCompanyExt(id=1330228550474510626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, companyId=1330228550461927713, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Qilu Pharmaceutical Co., Ltd., Jinan 250101, Shandong Province, China), AuthorCompanyExt(id=1330228550482899235, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, companyId=1330228550461927713, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=齐鲁制药有限公司,山东 济南 250101)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.09.020, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.09.020, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2022.09.020, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2022.09.020, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1662739200000, fullTextJson=null, articleText=null, reference=null)
收藏切换
胰高血糖素样肽-1受体激动剂对2型糖尿病患者的心血管结局
沈舒云
世界临床药物 | 综述评论 2022,43(9): 1199-1206
收起
收藏切换
世界临床药物 |综述评论 2022 , 43 (9) : 1199 -1206
胰高血糖素样肽-1受体激动剂对2型糖尿病患者的心血管结局
全屏
[Author(id=1330228550550008101, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330228550621311271, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, authorId=1330228550550008101, language=EN, stringName=Shuyun SHEN, firstName=Shuyun, middleName=null, lastName=SHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Qilu Pharmaceutical Co., Ltd., Jinan 250101, Shandong Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228550696808744, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, authorId=1330228550550008101, language=CN, stringName=沈舒云, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=齐鲁制药有限公司,山东 济南 250101, bio={"content":"

沈舒云,工程师,研究方向:仿制药选题。

"}, bioImg=null, bioContent=

沈舒云,工程师,研究方向:仿制药选题。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228550461927713, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, xref=null, ext=[AuthorCompanyExt(id=1330228550474510626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, companyId=1330228550461927713, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Qilu Pharmaceutical Co., Ltd., Jinan 250101, Shandong Province, China), AuthorCompanyExt(id=1330228550482899235, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228549761478940, companyId=1330228550461927713, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=齐鲁制药有限公司,山东 济南 250101)])])]
沈舒云
作者信息
  • 齐鲁制药有限公司,山东 济南 250101
作者简介:

沈舒云,工程师,研究方向:仿制药选题。

Progress on cardiovascular outcomes of glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes mellitus
Shuyun SHEN
Affiliations
  • Qilu Pharmaceutical Co., Ltd., Jinan 250101, Shandong Province, China
出版时间: 2022-09-10 doi: 10.13683/j.wph.2022.09.020
文章导航
收藏切换

胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1 RA)是一类新型降糖药物,由于降糖、减重效果突出且引发低血糖的风险较低,因此在2型糖尿病(type 2 diabetes mellitus,T2DM)的治疗中越来越重要。在过去的几年中,开发公司针对利拉鲁肽、艾塞那肽一周1次长效制剂、利司那肽、阿必鲁肽、度拉鲁肽、司美格鲁肽皮下注射剂和司美格鲁肽口服制剂,完成了7项心血管结局试验(cardiovascular outcome trial,CVOT),并发现所有GLP-1 RAs的心血管结果都非劣效于安慰剂,部分GLP-1 RAs具有优效性。这些试验结果改变了各国关于T2DM的药物治疗指南。该文综述了GLP-1 RAs的7项CVOTs,以期为临床用药提供更多的支持。

胰高血糖素样肽-1受体激动剂  /  2型糖尿病  /  脑血管疾病  /  心血管结局试验

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) is a new class of hypoglycemic drugs, which is increasingly important in the treatment of type 2 diabetes mellitus (T2DM) due to its outstanding effects of hypoglycemia, weight loss and low risk of hypoglycemia. Over the past several years, the developer has completed seven cardiovascular outcome trial (CVOT) involving liraglutide, once-weekly long-acting exenatide, lixisenatide, abirlutide, duraglutide, semaglutide as a subcutaneous injection, and semaglutide as an oral formulation. The cardiovascular outcomes of all GLP-1 RAs were found to be noninferior to placebo, and some GLP-1 RAs were found to be superior. The results of these trials have changed national guidelines for medical treatment of T2DM. This article reviewed 7 CVOTs of GLP-1 RAs, in order to provide more support for clinical medication.

glucagon-like peptide-1 receptor agonist  /  type 2 diabetes mellitus  /  cardiovascular disease  /  cardiovascular outcome trial
沈舒云. 胰高血糖素样肽-1受体激动剂对2型糖尿病患者的心血管结局. 世界临床药物, 2022 , 43 (9) : 1199 -1206 . DOI: 10.13683/j.wph.2022.09.020
Shuyun SHEN. Progress on cardiovascular outcomes of glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes mellitus[J]. World Clinical Drug, 2022 , 43 (9) : 1199 -1206 . DOI: 10.13683/j.wph.2022.09.020

参考文献 引证文献
排序方式:
[1]
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志, 2021, 37(4): 311-398.
[2]
Matheus AS, Tannus LR, Cobas RA, et al. Impact of diabetes on cardiovascular disease: an update[J]. Int J Hypertens, 2013, 2013: 653789.
[3]
FDA. BYETTA®(exenatide) prescribing information[DB/OL]. (2021-11-04) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021773s044lbl.pdf.
[4]
FDA. BYDUREON®(exenatide extended-release) prescribing information[DB/OL]. (2021-07-22) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022200s031lbl.pdf.
[5]
FDA. VICTOZA®(liraglutide) prescribing information[DB/OL]. (2020-11-20) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022341s036lbl.pdf.
[6]
FDA. ADLYXIN (lixisenatide) prescribing information[DB/OL]. (2021-07-30) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208471s004lbl.pdf.
[7]
FDA. TRULICITY (dulaglutide) prescribing information[DB/OL]. (2021-09-30) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125469s044lbl.pdf.
[8]
FDA. OZEMPIC (semaglutide) prescribing information[DB/OL]. (2021-04-12) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209637s008lbl.pdf.
[9]
FDA. RYBELSUS (semaglutide) prescribing information[DB/OL]. (2021-04-30) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213051s006lbl.pdf.
[10]
FDA. XULTOPHY® 100/3.6 (insulin degludec and liraglutide) prescribing information[DB/OL]. (2019-11-15) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208583s014s015lbl.pdf.
[11]
FDA. SOLIQUA® 100/33 (insulin glargine and lixisenatide) prescribing information[DB/OL]. (2021-07-28) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208673s011lbl.pdf.
[12]
FDA. TANZEUM (albiglutide) prescribing information[DB/OL]. (2017-12-20) [2021-11-30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125431s020lbl.pdf.
[13]
FDA. Tanzeum®(albiglutide)–Drug discontinuation On July 26, 2017[DB/OL]. [2021-12-01]. https://professionals.optumrx.com/content/dam/optum3/professional-optumrx/news/rxnews/drug-recalls-shortages/drugwithdrawal_tanzeum_2017-0801.pdf.
[14]
FDA. Guidance document: diabetes mellitus–evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, 2008[EB/OL]. [2021-12-01]. https://www.fda.gov/regulatory-information/search-fdaguidance-documents/diabetes-mellitus-evaluating-cardiovascularrisk-new-antidiabetic-therapies-treat-type-2-diabetes.
[15]
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2016, 375(4): 311-322.
[16]
Mentz RJ, Bethel MA, Gustavson S, et al. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)[J]. Am Heart J, 2017, 187: 1-9.
[17]
Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2017, 377(13): 1228-1239.
[18]
Bentley-Lewis R, Aguilar D, Riddle MC, et al. Rationale, design, and baseline characteristics in evaluation of lixisenatide in acute coronary syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo[J]. Am Heart J, 2015, 169(5): 631-638.
[19]
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome[J]. N Engl J Med, 2015, 373(23): 2247-2257.
[20]
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial[J]. Lancet, 2019, 394(10193): 121-130.
[21]
Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial[J]. Lancet, 2018, 392(10157): 1519-1529.
[22]
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2016, 375(19): 1834-1844.
[23]
Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2019, 381(9): 841-851.
[24]
American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021[J]. Diabetes Care, 2021, 44(Suppl 1): S125-S150.
[25]
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD[J]. Eur Heart J, 2020, 41(2): 255-323.
[26]
国家卫生健康委员会能力建设和继续教育中心, 孙艺红, 陈康, 等. 糖尿病患者合并心血管疾病诊治专家共识[J]. 中华内科杂志, 2021, 60(5): 421-437.
[27]
Longato E, Di Camillo B, Sparacino G, et al. Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes[J]. Eur J Prev Cardiol, 2021, 28(1): 22-29.
[28]
Caruso I, Cignarelli A, Giorgino F. Heterogeneity and similarities in GLP-1 receptor agonist cardiovascular outcomes trials[J]. Trends Endocrinol Metab, 2019, 30(9): 578-589.
2022年第43卷第9期
15
2
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2022.09.020
  • 接收时间:2022-03-14
  • 首发时间:2026-11-19
  • 出版时间:2022-09-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-03-14
基金
作者信息
    齐鲁制药有限公司,山东 济南 250101
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.09.020
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏